Is RNW a Good Stock to Buy? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on A signed $7.02 cash deal now sets the price, with revenue (fy26, ended march 2026) at ~₹150.6 billion (~$1.6 billion). The bear case rests on deal completion is now the first risk: until the scheme is approved and sanctioned, a regulatory, financing or vote problem could break it, and the December 2025 collapse shows that can happen here. Analysts covering it are spread from $7.05 to $8.70, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Deal completion is now the first risk: until the scheme is approved and sanctioned, a regulatory, financing or vote problem could break it, and the December 2025 collapse shows that can happen here. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $7.05, +2.9% from the $6.85 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

A signed $7.02 cash deal now sets the price. CPP Investments and Sinha, who together with affiliates already control the majority, proposed ~$6.75 per share in May 2026, raised to a best-and-final ~$7.02 for the minority shares, and ReNew announced a binding agreement at $7.02 in cash on August 11, 2026. The most optimistic analyst target on RNW is $8.70, +27.0% from the $6.85 price. That figure is only reachable if this thesis works close to its best case.

Deal completion is now the first risk: until the scheme is approved and sanctioned, a regulatory, financing or vote problem could break it, and the December 2025 collapse shows that can happen here. Outside the deal, leverage dominates the risk picture: ~$7.3 billion of net debt against a ~$2.5 billion market value means refinancing terms and Indian rate moves hit equity holders before they hit anything else, and the reported dollar figures also carry rupee translation risk. Cash conversion depends on Indian state distribution companies and other offtakers paying on time, a recurring sore point across the sector. In manufacturing, global module and cell oversupply can compress the segment's margins quickly, and policy support tied to domestic content can be reset by regulation. Deal risk cuts both ways: the shares could fall back toward standalone value (the 52-week low is $4.39) if the scheme fails as the prior consortium attempt did, while upside is capped near $7.02 if it succeeds, and accepting the rollover would leave a holder in an illiquid private vehicle controlled by the buyers. As a foreign private issuer, ReNew files 20-F annual reports and 6-K updates rather than 10-Qs, so US holders get less frequent mandated disclosure than a domestic filer provides. The most pessimistic published target is $7.05, +2.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

India's second-largest utility-scale renewables operator, running wind, solar, hydro, transmission and manufacturing segments.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (A signed $7.02 cash deal now sets the price) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (deal completion is now the first risk: until the scheme is approved and sanctioned, a regulatory, financing or vote problem could break it, and the December 2025 collapse shows that can happen here) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

RNW is ReNew Energy Global plc, listed on Nasdaq as Class A ordinary shares. It is incorporated in England and Wales but operates almost entirely in India, where it owns ~13.1 GW of commissioned wind, solar and hydro generation plus transmission lines and solar manufacturing. It is the subject of a binding $7.02 per share cash take-private agreement announced August 11, 2026.

Neither an ADR nor a US domestic share exactly. RNW is a UK-incorporated company's Class A ordinary shares listed directly on Nasdaq, a structure created by its 2021 merger with the SPAC RMG Acquisition Corp II. It files as a foreign private issuer, meaning 20-F annual reports and 6-K updates instead of 10-Qs.

Yes, under a signed deal. A consortium of CPP Investments and founder-CEO Sumant Sinha proposed ~$6.75 per share in May 2026 for the shares they do not already own, then moved to a best-and-final ~$7.02, and on August 11, 2026 ReNew announced a binding agreement at $7.02 in cash through a UK scheme of arrangement. It still needs scheme shareholder approval and court sanction, and had not completed as of October 16, 2026, when the stock closed at $6.88. An earlier consortium attempt was abandoned in December 2025 after Masdar withdrew.